Anti-CD40 targeted fusion proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8961991
SERIAL NO

12717789

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
BAYLOR RESEARCH INSTITUTE2001 BRYAN ST STE 2200 DALLAS TX 75201

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Banchereau, Jacques F Dallas, US 94 1432
Flamar, Anne-Laure Dallas, US 23 785
Levy, Yves Paris, FR 37 390
Montes, Monica Dallas, US 9 321
Zurawski, Gerard Midlothian, US 85 1489

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 24, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00